RecruitingPhase 3NCT05035342

Fecal Transplantation to Eradicate Colonizing Emergent Superbugs


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

214 participants

Start Date

Jan 11, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Carriage of multi-drug and extensive-drug resistant Gram negative bacteria (MDR-GNB) is associated with an increased risk of infections by these bacteria for the carriers and a high risk of dissemination both in the healthcare setting and the community; the main MDR-GNB reservoir is the fecal microbiota. To prevent both infections and dissemination, effective measures to decolonize subjects carrying MDR-GNB are urgently needed. Animal models, case reports and cohort studies suggest fecal microbiota transplantation (FMT) may be efficient for MDR-GNB decolonization.


Eligibility

Min Age: 18 YearsMax Age: 105 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Fecal Microbiota Transplantation (FMT) capsules and a biological treatment called Placebo capsules for people with enterobacteriaceae infections and fecal microbiota transplantation. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years to 105 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALFecal Microbiota Transplantation (FMT) capsules

Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).

BIOLOGICALPlacebo capsules

The "placebo" FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules.


Locations(11)

Beaujon Hospital

Clichy, France

Henri Mondor Hospital

Créteil, France

Raymond Poincaré Hospital

Garche, France

Bicêtre Hospital

Le Kremlin-Bicêtre, France

Bichat Hospital

Paris, France

Bichat Hospital

Paris, France

La Pitié Salpêtrière Hospital

Paris, France

Lariboisière Hospital

Paris, France

Saint Antoine Hospital

Paris, France

Saint Louis Hospital

Paris, France

Tenon Hospital

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05035342


Related Trials